Abstract
Background: TNFα inhibitors are the first line biological treatment for patients suffering from rheumatic diseases (RD) and inflammatory bowel disease (IBD). Limited information is available about long-term treatment patterns of patients starting a TNFα inhibitor and whether these differ between patients suffering from RD and IBD. Objectives: To compare treatment
... read more